Nasal-type NK/T-cell lymphoma successfully treated with ProMACE-CytaBOM therapy

Dermatology. 2004;209(3):243-5. doi: 10.1159/000079901.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bleomycin / administration & dosage
  • Cyclophosphamide / administration & dosage
  • Cytarabine / administration & dosage
  • Doxorubicin / administration & dosage
  • Etoposide / administration & dosage
  • Facial Neoplasms / drug therapy*
  • Facial Neoplasms / pathology
  • Humans
  • Killer Cells, Natural / pathology
  • Lymphoma, T-Cell, Cutaneous / drug therapy*
  • Lymphoma, T-Cell, Cutaneous / pathology
  • Male
  • Methotrexate / administration & dosage
  • Prednisone / administration & dosage
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology
  • Vincristine / administration & dosage

Substances

  • Cytarabine
  • Bleomycin
  • Vincristine
  • Etoposide
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone
  • Methotrexate

Supplementary concepts

  • PROMACE-CytaBOM protocol